文献速递类风湿关节炎

PF-06651600(Ritlecitinib)治疗中重度类风湿关节炎的疗效与安全性

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
PubMed 文献 · Arthritis Rheumatol · 2020-09-07

第8周时PF-06651600组SDAI评分较基线的平均变化大于安慰剂组,且总体耐受性良好。

要点

  • PF-06651600组第8周SDAI评分平均变化为-26.1,安慰剂组为-16.8,差异有统计学意义。
  • 多数不良事件为轻度,未报告治疗相关严重不良事件、重度不良事件或死亡。
  • 最常见不良事件类别为感染及侵染类疾病和皮肤及皮下组织疾病。

核心结论

  • 口服JAK3/TEC抑制剂PF-06651600 200mg每日一次可显著改善RA疾病活动度,且在该小型8周研究中总体耐受性良好。

研究设计与样本

  • 入组患者对甲氨蝶呤应答不足,研究设计允许最多50%的患者既往接受过1种疗效不足和/或不耐受的TNF抑制剂。

主要发现

  • 第8周SDAI评分较基线的平均变化在PF-06651600组为-26.1(95%可信区间-29.7,-22.4),安慰剂组为-16.8(95%可信区间-20.9,-12.7),P<0.001。
  • 多数不良事件为轻度,未报告治疗相关严重不良事件、重度不良事件或死亡。
  • 最常见不良事件类别为感染及侵染类疾病以及皮肤和皮下组织疾病;PF-06651600组有1例轻度单纯疱疹被认为与治疗相关,3天内缓解,未停药或使用抗病毒治疗。

关键数值与推荐

  • 主要终点为第8周SDAI评分较基线的变化,采用贝叶斯分析并以安慰剂反应的信息性先验分布进行评估。

临床怎么用

  • 对于甲氨蝶呤应答不足的中重度血清阳性RA患者,PF-06651600 200mg每日一次可能改善疾病活动度且耐受性良好,但需更大样本和更长疗程验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of PF-06651600 (ritlecitinib), an irreversible inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, in comparison with placebo in patients with rheumatoid arthritis (RA). METHODS: An 8-week, phase II, double-blind, parallel-group study was conducted. Seventy patients who were seropositive for anti-citrullinated protein antibodies and/or rheumatoid factor were randomized 3:2 to receive oral PF-06651600 (200 mg once daily) or placebo for 8 weeks. Eligible patients had an inadequate response to methotrexate, and the study design allowed up to 50% of patients to have previously received 1 tumor necrosis factor inhibitor that was inadequately effective and/or not tolerated. The primary end point was change from baseline in the Simplified Disease Activity Index (SDAI) score at week 8, assessed by Bayesian analysis using an informative prior distribution for placebo response. RESULTS: Mean change from baseline in the SDAI score at week 8 was greater in the PF-06651600 group (-26.1 [95% credible interval -29.7, -22.4]) than in the placebo group (-16.8 [95% credible interval -20.9, -12.7]; P < 0.001). Most adverse events (AEs) were mild in severity, and no treatment-related serious AEs, severe AEs, or deaths were reported. The most common classes of AE were infections and infestations as well as skin and subcutaneous tissue disorders; there was 1 mild case of herpes simplex in the PF-06651600 group that was considered to be treatment related, which resolved within 3 days without study treatment discontinuation or antiviral therapy. CONCLUSION: Treatment with the oral JAK3/TEC inhibitor PF-06651600 (200 mg once daily) was associated with significant improvements in RA disease activity and was generally well-tolerated in this small 8-week study.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Robinson MF, Damjanov N, Stamenkovic B, et al. Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2020. PMID: 32419304. doi:10.1002/art.41316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。